TY - JOUR
T1 - An aggressive early gastric cancer: Kodama's PenA type
AU - Morgagni, Paolo
AU - Solaini, Leonardo
AU - Saragoni, Luca
AU - Bencivenga, Maria
AU - Fumagalli Romario, Uberto
AU - Graziosi, Luigina
AU - Marino, Elisabetta
AU - Marrelli, Daniele
AU - Rausei, Stefano
AU - Rosa, Fausto
AU - Scarpi, Emanuela
AU - Tomezzoli, Anna
AU - Tringali, Domenico
AU - Vindigni, Carla
AU - Vittimberga, Giovanni
AU - Roviello, Franco
PY - 2018
Y1 - 2018
N2 - Background: To investigate the role of Kodama PenA subtype in influencing survival in patients with early gastric cancer (EGC).Methods: All patients surgically treated for EGC at 7 Italian centers (Forli, Varese, Siena, Verona, Milan, Rome and Perugia) belonging to the Italian Research Group for Gastric Cancer (GIRCG) from January 1982 and December 2009 were included.Results: PenA patients were 230 (21.5%) while other types were 839 (78.5%). Nodal metastases were more common in PenA (30.7%) than non-PenA (10.4%) EGCs. Among preoperative variables, only age (OR 1.02; 95% CI 1.00-1.03, p = 0.009) and macrotype Ill (OR 1.95; 95% CI 1.39-2.75, p = 0.0001) were significantly associated with Pen A type. Survival analysis performed on NO patients demonstrated that only size >2 cm (HR 1.85; 95% Cl 1.12-3.05, p = 0.017) and age (HR 1.06; 95% CI 1.03-1.08, p < 0.0001) were independent poor prognostic factor. Among N+ patients age (HR 1.04; 95% CI 1.00-1.07, p = 0.048), number of positive lymph nodes (HR 1.13; 95% CI 1.05-1.20, p = 0.0002) and PenA (HR 4.23; 95% CI 1.70 -10.55, p = 0.002) were significantly correlated with poor prognosis at multivariate analysis.Conclusions: Kodama PenA subtype was the most powerful independent prognostic factor in patients with nodal metastases. Its status should always be investigated in EGCs patients. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
AB - Background: To investigate the role of Kodama PenA subtype in influencing survival in patients with early gastric cancer (EGC).Methods: All patients surgically treated for EGC at 7 Italian centers (Forli, Varese, Siena, Verona, Milan, Rome and Perugia) belonging to the Italian Research Group for Gastric Cancer (GIRCG) from January 1982 and December 2009 were included.Results: PenA patients were 230 (21.5%) while other types were 839 (78.5%). Nodal metastases were more common in PenA (30.7%) than non-PenA (10.4%) EGCs. Among preoperative variables, only age (OR 1.02; 95% CI 1.00-1.03, p = 0.009) and macrotype Ill (OR 1.95; 95% CI 1.39-2.75, p = 0.0001) were significantly associated with Pen A type. Survival analysis performed on NO patients demonstrated that only size >2 cm (HR 1.85; 95% Cl 1.12-3.05, p = 0.017) and age (HR 1.06; 95% CI 1.03-1.08, p < 0.0001) were independent poor prognostic factor. Among N+ patients age (HR 1.04; 95% CI 1.00-1.07, p = 0.048), number of positive lymph nodes (HR 1.13; 95% CI 1.05-1.20, p = 0.0002) and PenA (HR 4.23; 95% CI 1.70 -10.55, p = 0.002) were significantly correlated with poor prognosis at multivariate analysis.Conclusions: Kodama PenA subtype was the most powerful independent prognostic factor in patients with nodal metastases. Its status should always be investigated in EGCs patients. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
KW - Early gastric cancer
KW - Histotype
KW - Lymph node metastases
KW - Prognosis
KW - Prognostic factors
KW - Early gastric cancer
KW - Histotype
KW - Lymph node metastases
KW - Prognosis
KW - Prognostic factors
UR - https://publicatt.unicatt.it/handle/10807/223394
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85049981556&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85049981556&origin=inward
U2 - 10.1016/j.ejso.2018.03.016
DO - 10.1016/j.ejso.2018.03.016
M3 - Article
SN - 0748-7983
VL - 44
SP - 1186
EP - 1190
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 8
ER -